Emmessar Biotech & Nutrition Limited (BOM:524768)
28.07
-0.47 (-1.65%)
At close: Jan 20, 2026
BOM:524768 Revenue
Emmessar Biotech & Nutrition had revenue of 6.30M INR in the quarter ending September 30, 2025, a decrease of -25.83%. This brings the company's revenue in the last twelve months to 20.06M, down -12.48% year-over-year. In the fiscal year ending March 31, 2025, Emmessar Biotech & Nutrition had annual revenue of 21.35M with 4.55% growth.
Revenue (ttm)
20.06M
Revenue Growth
-12.48%
P/S Ratio
6.35
Revenue / Employee
1.25M
Employees
16
Market Cap
127.40M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 21.35M | 929.00K | 4.55% |
| Mar 31, 2024 | 20.42M | -4.73M | -18.82% |
| Mar 31, 2023 | 25.15M | 7.42M | 41.83% |
| Mar 31, 2022 | 17.73M | -66.83M | -79.03% |
| Mar 31, 2021 | 84.56M | 37.03M | 77.89% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sunrest Lifescience | 520.34M |
| Cian Healthcare | 232.80M |
| Beryl Drugs | 191.97M |
| Unjha Formulations | 141.50M |
| Zenith Healthcare | 112.08M |
| Norris Medicines | 72.84M |
| Hamps Bio | 71.20M |
| Desh Rakshak Aushdhalaya | 62.53M |